I’ve been in IT long enough to know that most people don’t think about supply chains until something breaks. Then suddenly everyone’s an expert. We’re seeing that play out right now with pharmaceutical supply chains, and honestly, it’s both predictable and frustrating.
A conflict in West Asia doesn’t sound like it should matter to hospitals in India or Southeast Asia, right? Wrong. That’s the kind of magical thinking that got us here in the first place. Geopolitical instability has real, immediate consequences for the movement of goods across the globe. And the pharmaceutical industry—which depends on intricate, fragile networks of manufacturing and distribution—is particularly exposed.
The Illusion of Independence That Wasn’t Really There
Here’s what bothers me most: we already knew this was a problem. Not the specific conflict, obviously, but the fundamental vulnerability. For years, companies and governments built supply chains that looked great on a spreadsheet. Maximum efficiency. Minimum redundancy. Just-in-time delivery. Beautiful from an accounting perspective. Terrible from a “what happens when something actually goes wrong” perspective.
India and ASEAN countries thought they had manufacturing independence. In some areas, they do. But that independence is often illusory. You can make the drugs locally, sure. But the raw materials? The critical ingredients? Often sourced from just a few suppliers, sometimes from unstable regions. Add in logistics routes that rely on a handful of shipping corridors, and you’ve got a system that looks resilient until it isn’t.
When conflict disrupts shipping lanes or creates uncertainty about trade routes, suddenly that cost-saving supply chain doesn’t look so clever anymore. Hospitals run out of essentials. Prices spike. People die. And everyone acts shocked.
The Real Cost of Putting All Your Eggs in One Basket
What we’re looking at here is risk concentration. It’s something I’ve seen play out in IT infrastructure for decades. Companies build systems that work perfectly right up until they don’t. Then they fail catastrophically.
In the pharmaceutical world, the consequences are more serious than a website going down. We’re talking about:
- Essential medicines becoming unavailable
- Treatment delays that affect patient outcomes
- Price volatility that hurts the poorest people hardest
- Governments scrambling to manage crises they should have seen coming
The solution sounds simple: diversify. Build redundancy. Keep buffer stock. Develop alternative suppliers. Create backup routes. But here’s the catch—it costs money upfront. It reduces efficiency metrics. Shareholders don’t like it. So companies don’t do it.
Instead, they optimize for today. And tomorrow’s crisis becomes somebody else’s problem.
What Actually Needs to Change
If we’re being honest, this isn’t a new vulnerability. It’s a known vulnerability that we collectively chose to ignore because it was profitable to do so. The question now is whether we actually learn anything from this disruption.
Real change would mean:
- Regional governments investing in domestic manufacturing capacity for critical medicines
- Companies building genuine redundancy into their supply chains, not just talking about it
- International cooperation on supply chain transparency and risk management
- Accepting that some efficiency has to be sacrificed for stability
Will it happen? Probably not at the scale needed. There’s still too much money in the current system, and changing it requires coordination between private companies, multiple governments, and international bodies. That’s hard. Harder than just hoping the next crisis doesn’t happen.
But here’s what I know: vulnerability doesn’t go away because you ignore it. It just waits for the right moment to cause maximum damage. We’ve built complex, interdependent systems that work brilliantly right up until they fail. The pharmaceutical supply chain is just one example among many.
The real question isn’t whether something will disrupt these systems again. It’s whether we’ll be any smarter about planning for it when it does.
Sarah Mitchell
Rachel Adams
Tom Harrington